State‐of‐the‐Art Clinical Article: Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Investigations over the past 20 years have demonstrated that antibacterials can vary markedly in the time course of antimicrobial activity. These differences in pharmacodynamic activity have implications for optimal dosage regimens. The results of more recent studies suggest that the magnitude of the pharmacokinetic/pharmacodynamic parameters required for efficacy are relatively similar in animal infection models and in human infections. However, there is still much to learn. Additional studies are needed to further correlate pharmacokinetic/pharmacodynamic parameters for many antibacterials with therapeutic efficacy in a variety of animal infection models and in human infections. The potential value of using pharmacokinetic/pharmacodynamic parameters as guides for establishing optimal dosing regimens for new and old drugs and for new emerging pathogens and resistant organisms, for setting susceptibility breakpoints, and for reducing the cost of drug development should make the continuing search for the therapeutic rationale of antibacterial dosing of mice and men worthwhile.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Moore, R. D., Lietman, P. S., & Smith, C. R. (1987) · Journal of Infectious Diseases · doi:10.1093/infdis/155.1.93 · Cited by 1,139 · cited 1×
“However, the opposite was observed in the major clinical trials correlating pharmacokinetic/pharmacodynamic parameters with the therapeutic efficacy of aminoglycosides [56].”
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
Forrest, A., Nix, D. E., Ballow, C. H., Goss, T. F., Birmingham, M. C., & Schentag, J. J. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.5.1073 · Cited by 1,101 · cited 2×
“[52] found that a 24-hour AUC/MIC value of > 125 was associated with satisfactory outcome for seriously ill patients treated with intravenous ciprofloxacin.”
Pallares, R., Liñares, J., Vadillo, M., Cabellos, C., Manresa, F., Viladrich, P. F., Martin, R., & Gudiol, F. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508243330802 · Cited by 773
Correlation of Antimicrobial Pharmacokinetic Parameters with Therapeutic Efficacy in an Animal Model
Vogelman, B., Gudmundsson, S., Leggett, J., Turnidge, J., Ebert, S., & Craig, W. A. (1988) · The Journal of Infectious Diseases · doi:10.1093/infdis/158.4.831 · Cited by 720 · cited 3×
“need to exceed the MIC for 100% of the dosing interval to exert a significant antibacterial effect [25-27, 36].”
Self-citationCraig, W. A. (1995) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/0732-8893(95)00053-d · Cited by 618 · cited 5×
“Several investigators have used multiple dosage regimens in animal infection models to correlate specific pharmacokinetic/pharmacodynamic parameters with the efficacy of various antibacterials against both gram-positive and gram-negative bacilli [9, 25-31].”
InfluentialSelf-citationBlaser, J., Stone, B. B., Groner, M. C., & Zinner, S. H. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.7.1054 · Cited by 481
Pharmacokinetics and pharmacodynamics of antibiotics in otitis media
CRAIG, W. A., & ANDES, D. (1996) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199603000-00015 · Cited by 435 · cited 3×
“pneumoniae and Haemophilus influenzae in patients with otitis media [38, 43].”
InfluentialSelf-citationDrusano, G. L., Johnson, D. E., Rosen, M., & Standiford, H. C. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.3.483 · Cited by 426 · cited 2×
“there is a significant risk of the emergence of resistant subpopulations [29].”
Leggett, J. E., Fantin, B., Ebert, S., Totsuka, K., Vogelman, B., Calame, W., Mattie, H., & Craig, W. A. (1989) · Journal of Infectious Diseases · doi:10.1093/infdis/159.2.281 · Cited by 354
Self-citationKinetics of antimicrobial activity
Vogelman, B., & Craig, W. A. (1986) · The Journal of Pediatrics · doi:10.1016/s0022-3476(86)80754-5 · Cited by 315 · cited 4×
“PAE refers to the persistent suppression of bacterial growth following exposure to an antimicrobial [2, 7, 10].”
InfluentialSelf-citation
Cited by
Items 501–600 of 1,003
Maglio, D., Ong, C. T., Banevicius, M. A., Geng, Q., Nightingale, C. H., & Nicolau, D. P. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.6.1941-1947.2004 · Cited by 74
“The time-dependent pharmacodynamic profile of cephalosporins has been quite reliable in predicting treatment outcomes in various infection models (4) and, to a more limited extent, in clinical practice (5).”
BackgroundBush, K., & Page, M. G. P. (2017) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-017-9506-4 · Cited by 73
Felton, T., Hope, W. W., & Roberts, J. A. (2014) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2014.04.007 · Cited by 73
“Three measures of drug exposure are commonly used to link drug exposure with bacterial killing (Craig 1998; Drusano 2004; Ambrose et al. 2007).”
BackgroundWatabe, S., Yokoyama, Y., Nakazawa, K., Shinozaki, K., Hiraoka, R., Takeshita, K., & Suzuki, Y. (2010) · Journal of Chromatography B · doi:10.1016/j.jchromb.2010.04.012 · Cited by 73
Residual Kidney Function and Peritoneal Dialysis–Associated Peritonitis Treatment Outcomes
Whitty, R., Bargman, J. M., Kiss, A., Dresser, L., & Lui, P. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00630117 · Cited by 73
Pharmacokinetics and Pharmacodynamics of β‐Lactamase Inhibitors
Crass, R. L., & Pai, M. P. (2018) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2210 · Cited by 73
“Vaborbactam Bacterial killing by the boronic acid derivative, VAB, in combination with meropenem appears to be best predicted by fAUC/MIC.76 Data from murine thigh models identified VAB fAUC/MIC targets of 9 and 38 to achieve stasis and 1-log killing, respectively, against KPCproducing Enterobacteriales.76 In a hollow…”
BackgroundInfluentialMathers, J. J., Flick, S. C., & Cox, L. A. (2011) · Environment International · doi:10.1016/j.envint.2011.01.014 · Cited by 73
Gatifloxacin, an Advanced 8‐Methoxy Fluoroquinolone
Fish, D. N., & North, D. S. (2001) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.21.1.35.34440 · Cited by 73
“Whether either the Cmax:MIC ratio or AUC24:MIC ratio is superior to the other parameter and which specific ratios are most predictive of drug efficacy remain somewhat controversial; however, strong relationships between these pharmacodynamic values and clinical and microbiologic outcomes during fluoroquinolone therapy…”
Pharmacokinetics and pharmacodynamics in critically ill patients
Varghese, J. M., Roberts, J. A., & Lipman, J. (2010) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0b013e328339ef0a · Cited by 72
Antibiotics and the burn patient
Ravat, F., Le-Floch, R., Vinsonneau, C., Ainaud, P., Bertin-Maghit, M., Carsin, H., & Perro, G. (2010) · Burns · doi:10.1016/j.burns.2009.10.006 · Cited by 73
Murillo, Ó., Domenech, A., Garcia, A., Tubau, F., Cabellos, C., Gudiol, F., & Ariza, J. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00523-06 · Cited by 72
“Based on previous experimental studies (13, 33, 43, 40), the definitive antibiotic doses were those achieving PD parameters in TCF that were similar to human ones in serum with conventional doses.”
MethodResultBulitta, J. B., Landersdorfer, C. B., Hüttner, S., Drusano, G. L., Kinzig, M., Holzgrabe, U., Stephan, U., & Sörgel, F. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00936-09 · Cited by 71
“PK-PD targets of 65% fT MIC for near-maximal bactericidal activity and of 40% fT MIC for bacteriostasis at 24 h were applied based on data from animal infection models (22, 25).”
BackgroundMethodOutcomes of extended infusion piperacillin/tazobactam for documented Gram-negative infections
Patel, G. W., Patel, N., Lat, A., Trombley, K., Enbawe, S., Manor, K., Smith, R. P., & Lodise, T. P. (2009) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2009.03.002 · Cited by 72
“…with an organism resistant to PT, 2) required dialysis, 3) required a solid organ or bone marrow transplant, 4) received a concurrent β-lactam antibiotic within 5 days after initiation of PT (fluoroquinolones and aminoglycosides were acceptable) (Craig, 1998), or 5) received N1 day of TI-PT.”
BackgroundAntimicrobial Stewardship in Surgery: Challenges and Opportunities
Tarchini, G., Liau, K. H., & Solomkin, J. S. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix087 · Cited by 72
Kasiakou, S. K., Lawrence, K. R., Choulis, N., & Falagas, M. E. (2005) · Drugs · doi:10.2165/00003495-200565170-00006 · Cited by 72
“as β-lactams, macrolides, clindamycin, linezolid, However, the optimal dose administration strategy quinupristin/dalfopristin and vancomycin.[10] Differof antimicrobial agents for the treatment of serious ent dose administration strategies for antibacterials”
BackgroundMethodInfluentialOlsen, K. M., Rudis, M. I., Rebuck, J. A., Hara, J., Gelmont, D., Mehdian, R., Nelson, C., & Rupp, M. E. (2004) · Critical Care Medicine · doi:10.1097/01.ccm.0000134832.11144.cb · Cited by 72
Continuous Clindamycin Infusion, an Innovative Approach to Treating Bone and Joint Infections
Zeller, V., Dzeing‐Ella, A., Kitzis, M.-D., Ziza, J.-M., Mamoudy, P., & Desplaces, N. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01081-09 · Cited by 72
“We chose to administer clindamycin by continuous infusion, as the pattern of in vitro bactericidal activity for clindamycin is time dependent (1, 5).”
BackgroundMethodInfluentialAntiretroviral Pharmacology in Mucosal Tissues
Thompson, C. G., Cohen, M. S., & Kashuba, A. D. M. (2013) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3182986ff8 · Cited by 71
“For example, although bacterial infections are extracellular, and the concentration of antimicrobials in the interstitial fluid is pharmacodynamically active (and can be measured with dialysis techniques or in blister fluid), the intracellular nature of HIV requires an understanding of active intracellular concentrati…”
BackgroundPharmacokinetics and Pharmacodynamics of Cefpirome in Subcutaneous Adipose Tissue of Septic Patients
Sauermann, R., Delle‐Karth, G., Marsik, C. L., Steiner, I. M., Zeitlinger, M. A., Mayer‐Helm, B., Georgopoulos, A. P., Müller, M., & Joukhadar, C. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.650-655.2005 · Cited by 71
“This finding is probably due to the fact that beta-lactams are most effective when T MIC is maximized (5, 11, 25, 28).”
BackgroundSowinski, K. M., Magner, S. J., Lucksiri, A., Scott, M. K., Hamburger, R. J., & Mueller, B. A. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02920707 · Cited by 71
“Aminoglycoside antibiotics are concentration-dependent bacteriocidal drugs and, as such, are most efficacious when high peak/MIC or AUC/MIC ratios are achieved (18).”
BackgroundInfluentialBiocompatible Nanocarrier Fortified with a Dipyridinium-Based Amphiphile for Eradication of Biofilm
Goswami, S., Thiyagarajan, D., Das, G. C., & Ramesh, A. (2014) · ACS Applied Materials & Interfaces · doi:10.1021/am504779t · Cited by 71
DeRyke, C. A., Kuti, J. L., & Nicolau, D. P. (2007) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.3.333 · Cited by 71
“With the cephalosporins, for instance, some authors suggest that maximum bactericidal activity might be achieved only after the fT>MIC is 70% instead of 50%, which we used.(22) Likewise, researchers identified a levofloxacin total-drug AUC:MIC ratio of 87 or more, instead of the traditional value of 125 established wi…”
BackgroundHow can we predict bacterial eradication?
Jacobs, M. R. (2003) · International Journal of Infectious Diseases · doi:10.1016/s1201-9712(03)90066-x · Cited by 71
Deziel, M. R., Heine, H. S., Louie, A., Kao, M. L., Byrne, W. R., Basset, J., Miller, L., Bush, K., KELLY, M. J., & Drusano, G. L. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.12.5099-5106.2005 · Cited by 71
“, the time above the agent’s MIC, the peak concentrations relative to the MIC, or the ratio of the area under the drug’s concentration-time curve to the MIC) is most predictive of the antimicrobial effect has facilitated the development of optimized treatment regimens (7, 8).”
BackgroundKarlowsky, J. A., Jones, M. E., Thornsberry, C., Evangelista, A. T., Yee, Y. C., & Sahm, D. F. (2005) · Clinical Infectious Diseases · doi:10.1086/426188 · Cited by 71
“Whether an individual MIC is studied or a population of MICs is studied as an MIC90, the AUC:MIC ratio is clinically predictive for fluoroquinolones [9].”
BackgroundLanggartner, J., Vasold, A., Glück, T., Reng, M., & Kees, F. (2008) · Intensive Care Medicine · doi:10.1007/s00134-008-1034-7 · Cited by 70
“concentration does not improve antibacterial activity [5].”
DeRyke, C. A., Banevicius, M. A., Fan, H. W., & Nicolau, D. P. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00752-06 · Cited by 70
“For the -lactams, the pharmacodynamic parameter that correlates best with antimicrobial efficacy is the fT MIC (3).”
BackgroundRight Dose, Right Now: Customized Drug Dosing in the Critically Ill
Roberts, J. A., Kumar, A., & Lipman, J. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002210 · Cited by 70
Use of botulinum toxin in the neurology clinic
Lim, E. C. H., & Seet, R. C. S. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.149 · Cited by 69
Blot, S. I., Lipman, J., Roberts, D. M., & Roberts, J. A. (2014) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2014.01.015 · Cited by 69
Gumbo, T., Pasipanodya, J. G., Nuermberger, E. L., Romero, K., & Hanna, D. L. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ426 · Cited by 69
Bouissou, F., Munzer, C., Decramer, S., Roussel, B., Novo, R., Morin, D., Lavocat, M. P., Guyot, C., Taque, S., Fischbach, M., et al. (2008) · PEDIATRICS · doi:10.1542/peds.2006-3632 · Cited by 69
Zeitlinger, M. A., Müller, M., & Joukhadar, C. (2005) · The AAPS Journal · doi:10.1208/aapsj070362 · Cited by 69
Servais, H., & Tulkens, P. M. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.9.2643-2647.2001 · Cited by 69
Schentag, J. J., Meagher, A. K., & Forrest, A. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1c199 · Cited by 69
Zhao, M., Lepak, A. J., VanScoy, B., Bader, J. C., Marchillo, K., Vanhecker, J., Ambrose, P. G., & Andes, D. R. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02542-17 · Cited by 68
Yokoyama, Y., Matsumoto, K., Ikawa, K., Watanabe, E., Shigemi, A., Umezaki, Y., Nakamura, K., Ueno, K., Morikawa, N., & Takeda, Y. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.02.012 · Cited by 68
“The fT > MIC 286 targets of β-lactam antibiotics (carbapenems, penicillins, and cephalosporins) required 287 for a static effect and near maximal bactericidal effects against organism were 20-40% 288 and 40-70%, respectively [8].”
BackgroundMethodInfluentialPopulation Pharmacokinetics at Two Dose Levels and Pharmacodynamic Profiling of Flucloxacillin
Landersdorfer, C. B., Kirkpatrick, C. M. J., Kinzig‐Schippers, M., Bulitta, J. B., Holzgrabe, U., Drusano, G. L., & Sörgel, F. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01410-06 · Cited by 68
“The clinical outcome for treatment with beta-lactams is related to the proportion of the dosing interval for which nonprotein-bound plasma concentrations exceed the MIC (fT MIC) (12, 17).”
BackgroundJacobs, M., Grégoire, N., Couet, W. R., & Bulitta, J. B. (2016) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004782 · Cited by 68
“Such data have proven useful to optimize antibiotic monotherapy regimens for patients [2, 11, 12].”
BackgroundPharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections
Takeda, Y., Matsumoto, K., Watanabe, E. M., Kanazawa, N., Fukamizu, T., Shigemi, A., Yokoyama, Y., Ikawa, K., & Morikawa, N. (2016) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s96143 · Cited by 68
In Vitro Pharmacokinetic/Pharmacodynamic Models in Anti-Infective Drug Development: Focus on TB
Vaddady, P. K., Lee, R. E., Jr., & Meibohm, B. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.224 · Cited by 68
“In other words, concentrationdependent antibiotics tend to have larger PAEs [14].”
BackgroundBarbour, A., Scaglione, F., & Derendorf, H. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.01.023 · Cited by 69
Canet, J.-J., & Garau, J. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkf507 · Cited by 68
Optimizing the Use of Beta-Lactam Antibiotics in Clinical Practice: A Test of Time
Tilanus, A., & Drusano, G. L. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad305 · Cited by 67
“Based on in vitro and in vivo experiments with rodents, Eagle et al [1], and decades later Craig [2], were among the first to postulate that the relationship between antibiotic exposure and microbiological effects can be separated in antibiotics that show timedependent and concentration-dependent killing effects [1, 2…”
Jumbe, N. L. ‘., Louie, A., Miller, M. H., Liu, W., Deziel, M. R., Tam, V. H., Bachhawat, R., & Drusano, G. L. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.1.310-317.2006 · Cited by 67
Kristoffersson, A., David‐Pierson, P., Parrott, N. J., Kuhlmann, O., Lavé, T., Friberg, L. E., & Nielsen, E. I. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1856-x · Cited by 67
Pharmacokinetics and pharmacodynamics in antibiotic dose optimization
Sy, S. K. B., Zhuang, L., & Derendorf, H. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2016.1123250 · Cited by 67
“[10,11] In the 1990s, Craig expanded on the concept of PD indices through a number of rodent studies correlating PK parameters with bacterial kill over 24 h.[12] This PK-PD information is very useful in the selection of the dose and dosing regimen for antimicrobial candidates entering the clinical stage of drug develo…”
BackgroundMachuca, J., Ortiz-Padilla, M., Recacha, E., Díaz-De-Alba, P., Docobo-Pérez, F., Rodríguez-Martínez, J. M., & Pascual, Á. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw258 · Cited by 67
Immune Checkpoint Targets for Host-Directed Therapy to Prevent and Treat Leishmaniasis
Kumar, R., Chauhan, S. B., Ng, S. S., Sundar, S., & Engwerda, C. R. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01492 · Cited by 67
Respiratory Syncytial Virus Infection in Adults
Murata, Y., & Falsey, A. R. (2007) · Antiviral Therapy · doi:10.1177/135965350701200s03.1 · Cited by 68
Clinical Efficacy of Newer Agents in Short-Duration Therapy for Community-Acquired Pneumonia
File, T. M. (2004) · Clinical Infectious Diseases · doi:10.1086/421354 · Cited by 67
“Providers can use their knowledge of each antibiotic’s known pharmacodynamic profile to select the most appropriate agent, dosing amount, interval, and duration [8, 9].”
BackgroundHigher Cefazolin Concentrations with Intraosseous Regional Prophylaxis in TKA
Young, S. W., Zhang, M., Freeman, J. T., Vince, K. G., & Coleman, B. (2012) · Clinical Orthopaedics and Related Research · doi:10.1007/s11999-012-2469-2 · Cited by 66
Herendael, B. V., Jeurissen, A., Tulkens, P. M., Vlieghe, E., Verbrugghe, W., Jorens, P. G., & Ieven, M. M. (2012) · Annals of Intensive Care · doi:10.1186/2110-5820-2-22 · Cited by 66
Patel, N., Scheetz, M. H., Drusano, G. L., & Lodise, T. P. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00296-09 · Cited by 66
“For beta-lactams like TZP, it appears that bactericidal activity is optimized when fT MIC exceeds 50% of the dosing interval (designated 50% fT MIC) (8, 10).”
MethodNichols, K. R., Chung, E. K., Knoderer, C. A., Buenger, L. E., Healy, D. P., Dees, J., Crumby, A. S., & Kays, M. B. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02089-15 · Cited by 66
“For penicillin antibiotics like piperacillin, microbiological and clinical outcomes are associated with the cumulative percentage of the dosing interval that the drug concentration exceeds the MIC for the organism(s) under steady-state pharmacokinetic conditions (TMIC); optimal activity is seen when the TMIC is 50% (1…”
BackgroundZar, H. J., Jeena, P. M., Argent, A. C., Gie, R. P., & Madhi, S. A. (2005) · PubMed · Cited by 66
Sheu, C., Lin, S., Chang, Y.-T., Lee, C.-Y., Chen, Y., & Hsueh, P. (2018) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2018.1436966 · Cited by 66
Burgess, D. S., & Waldrep, T. W. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)80021-2 · Cited by 66
Hoberman, A., Dagan, R., Leibovitz, E., Rosenblüt, A., Johnson, C. E., Huff, A., Bandekar, R. R., & Wynne, B. (2005) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000164794.50281.1a · Cited by 66
Pallarés, R., Fenoll, A., & Liñares, J. (2003) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2003.08.004 · Cited by 66
“h, have both sufficient activity and good pharmacokinetic/pharmacodynamic factors to provide inhibitory levels for a substantial portion of the dosing period for pneumococci with intermediate penicillin resistance and even for resistant strains [80].”
BackgroundInfluentialPallarés, R., Capdevila, O., Liñares, J., Grau, I., Onaga, H., Tubau, F., Schulze, M. H., Hohl, P., & Gudiol, F. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01162-2 · Cited by 66
Therapeutic drug monitoring of β-lactams for critically ill patients: unwarranted or essential?
Roberts, J. A., Hope, W. W., & Lipman, J. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.01.022 · Cited by 66
Frigoli, M., Krupa, M. P., Hooyberghs, G., Lowdon, J. W., Cleij, T. J., Diliën, H., Eersels, K., & van Grinsven, B. (2024) · Sensors · doi:10.3390/s24175576 · Cited by 65
“In fact, a key step during the development of novel antibiotics is translational Pharmacokinetic/Pharmacodynamic (PK/PD) studies, which require accurate antibiotic concentration measurements to predict the efficacy of antibiotics in animal models and humans [25,26].”
BackgroundIsla, A., Rodríguez‐Gascón, A., Maynar, J., Arzuaga, A., Toral, D., & Pedraz, J. L. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.05.004 · Cited by 65
Zobell, J. T., Young, D. C., Waters, C. D., Stockmann, C. R., Ampofo, K., Sherwin, C. M. T., & Spigarelli, M. G. (2012) · Pediatric Pulmonology · doi:10.1002/ppul.22655 · Cited by 65
“, 3–4 times MIC) and when the beta-lactam concentrations remain above the MIC for 20–40% of the dosing interval.(16,17,19) Carbapenems were derived from thienamycin, a compound produced by Streptomyces cattleya.”
BackgroundLepak, A. J., Marchillo, K., VanHecker, J., Diekema, D., & Andes, D. R. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01354-13 · Cited by 65
Ram, R., Halavy, Y., Amit, O., Paran, Y., Katchman, E. A., Yachini, B., Kor, S., Avivi, I. M., & Ben‐Ami, R. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy258 · Cited by 65
Diagnosis and treatment of upper respiratory tract infections in the primary care setting
Fendrick, A. M., Saint, S. K., Brook, I., Jacobs, M. R., Pelton, S. I., & Sethi, S. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80137-5 · Cited by 65
Gustafsson, I., Löwdin, E., Odenholt, I., & Cars, O. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.9.2436-2440.2001 · Cited by 65
Li, R. C., Zhu, M., & Schentag, J. J. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199937010-00001 · Cited by 65
“[22-24] Similarly, the Cmax : MIC ratio and AUC :MIC ratio are considered to be useful indicators for aminoglycoside antimicrobials.”
BackgroundSanz-Codina, M., Bozkır, H. Ö., Jorda, A., & Zeitlinger, M. A. (2023) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2023.03.018 · Cited by 64
Kuti, J. L., Kiffer, C. R. V., Mendes, C. M. F., & Nicolau, D. P. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2007.01885.x · Cited by 64
“The association of MIC distribution and pharmacokinetic data derived from microbiological and human studies through the use of pharmacodynamic models offers a more sophisticated tool for prediction of the outcome of infection [2].”
Hagihara, M., Wiskirchen, D. E., Kuti, J. L., & Nicolau, D. P. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05473-11 · Cited by 64
“In the current study, simulating free vancomycin exposures after a 1 g q8h dose, we anticipated poor bactericidal effects for isolates with vancomycin MICs of 2 g/ml because some studies have shown that a total AUC/MIC of 400 is needed for successful outcomes (6, 18, 24).”
BackgroundGarrigós, C., Murillo, Ó., Lora-Tamayo, J., Verdaguer, R., Tubau, F., Cabellos, C., Cabo, J., & Ariza, J. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01570-12 · Cited by 64
Frampton, J. E. (2013) · Drugs · doi:10.1007/s40265-013-0075-6 · Cited by 64
“percentage of the dosing interval) that the serum concentration of free drug exceeds the MIC (f %T [ MIC) of the pathogen [89].”
BackgroundEmpiric Antibiotics for Sepsis
Buckman, S. A., Turnbull, I. R., & Mazuski, J. E. (2018) · Surgical Infections · doi:10.1089/sur.2017.282 · Cited by 64
“Other considerations include the pharmacokinetic and pharmacodynamic properties of the agent, its bactericidal versus bacteriostatic activity, and its inherent toxicity [22, 23].”
Bernabeu‐Wittel, M., Pichardo, C., García-Curiel, A., Pachón-Ibáñez, M. E., Ibáñez-Martínez, J., Me, J.-M., & Pachón, J. (2005) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2005.01095.x · Cited by 64
“As already known, Cmax ⁄MIC is a key predictor of the antibacterial activity of aminoglycosides, and there is consensus that it should reach a value of ‡ 8 in order to ensure clinical efficacy [18].”
BackgroundInfluentialPharmacokinetics of levofloxacin after single intravenous and repeat oral administration to cats
Albarellos, G., Ambros, L., & Landoni, M. F. (2005) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/j.1365-2885.2005.00669.x · Cited by 64
“ratio, and peak serum concentration (Cmax)/MIC ratio, which also is an important predictor for avoiding the emergence of bacterial resistance (Dudley, 1991; Drusano et al., 1993; Schentag et al., 1993; Hyatt et al., 1995; Shojaee Aliabadi and Lees, 1997; Craig, 1998; Walker, 2000; Wright et al., 2000; Toutain et al.,…”
BackgroundDaily serum piperacillin monitoring is advisable in critically ill patients
Blondiaux, N., Wallet, F., Favory, R., Onimus, T., Nseir, S., Courcol, R., Durocher, A., & Roussel‐Delvallez, M. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.01.018 · Cited by 64
“the time during which the drug’s serum concentration remains above the MIC threshold (T>MIC) [3].”
Critical Issues in Therapeutic Drug Monitoring of Antiretroviral Drugs
van Heeswijk, R. P. G. (2002) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200206000-00001 · Cited by 64
Mouton, J. W., Punt, N. C., & Vinks, A. A. T. M. M. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.06.013 · Cited by 63
Kim, A., Banevicius, M. A., & Nicolau, D. P. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01252-07 · Cited by 63
“Like that of other carbapenems, doripenem efficacy was related to fT MIC (9, 28).”
BackgroundResultInfluentialPreclinical Efficacy Testing of New Drug Candidates
Nuermberger, E. L. (2017) · Microbiology Spectrum · doi:10.1128/microbiolspec.tbtb2-0034-2017 · Cited by 63
“In some studies, key PK/PD parameters and target exposures derived from HFS-TB experiments were used together with population PK data and wild-type MIC distributions to predict the probability of different clinical antibiotic doses achieving optimal drug exposures and rates of sterilizing effect in sputum in patient p…”
BackgroundInfluentialIndividualising Therapy to Minimize Bacterial Multidrug Resistance
Heffernan, A. J., Sime, F. B., Lipman, J., & Roberts, J. A. (2018) · Drugs · doi:10.1007/s40265-018-0891-9 · Cited by 63
Susceptibility Test Methods: General Considerations
Turnidge, J. D. (2015) · ASM Press eBooks · doi:10.1128/9781555817381.ch70 · Cited by 63
Kumar, G., Sharma, S., Shafiq, N., Pandhi, P., Khuller, G. K., & Malhotra, S. (2010) · Drug Delivery · doi:10.3109/10717544.2010.509367 · Cited by 63
“It has been noted that the C max /MIC ratio of 8–10 is a good efficacy predictor for aminoglycosides (Craig, 1998), in the case of fluoroquinolones, an AUC 24 /MIC ratio of 100–125 against gram-negative and 25–35 against grampositive organisms seems to be desirable (Schmidt et al.”
BackgroundAntibiotic Resistance in Streptococcus pneumoniae: What Does the Future Hold?
Nuermberger, E. L., & Bishai, W. R. (2004) · Clinical Infectious Diseases · doi:10.1086/382696 · Cited by 63
“Data from [20, 21], with the following exceptions: data for amoxicillin, 1 g t.”
Jacobs, M. R. (2000) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200005001-00008 · Cited by 63
A Fresh Look at the Definition of Susceptibility of Streptococcus pneumoniae to β-Lactam Antibiotics
Musher, D. M., Bartlett, J. G., & Doern, G. V. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.21.2538 · Cited by 63
Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting
Lepak, A., & Andes, D. (2011) · Critical Care Clinics · doi:10.1016/j.ccc.2010.11.001 · Cited by 62
Dalhoff, A. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00022-14 · Cited by 62
Nicasio, A. M., VanScoy, B. D., Mendes, R. E., Castanheira, M., Bulik, C. C., Okusanya, Ó. O., Bhavnani, S. M., Forrest, A., Jones, R. N., Friedrich, L. V., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02747-15 · Cited by 62
OPTIMIZING ANTIMICROBIAL PHARMACODYNAMICS: A GUIDE FOR YOUR STEWARDSHIP PROGRAM
Kuti, J. L. (2016) · Revista Médica Clínica Las Condes · doi:10.1016/j.rmclc.2016.08.001 · Cited by 62
“Antimicrobial killing characteristics are dependent on both the concentration of drug in relation to the minimum inhibitory concentration (MIC) and the time that this exposure is maintained (Figure 1) (5).”
Xiong, Y. Q., Estellés, A., Li, L., Abdelhady, W., Gonzales, R., Bayer, A. S., Tenorio, E., Leighton, A., Ryser, S., & Kauvar, L. M. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00904-17 · Cited by 62
“Maximal bactericidal effect is achieved when the free-drug concentration exceeds the targeted pathogen’s MIC by approximately 4-fold for 40 to 60% of the dosing interval (45).”
BackgroundLlor, C., Sierra, N., Hernandez, S. F., Moragas, A., Hernandez, M., Bayona, C., & Miravitlles, M. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn472 · Cited by 62
Daptomycin Pharmacokinetics in Adult Oncology Patients with Neutropenic Fever
Bubalo, J. S., Munar, M. Y., Cherala, G., Hayes‐Lattin, B., & Maziarz, R. T. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00943-08 · Cited by 62
“The extent of protein binding is identical between mice and humans; therefore, direct comparisons between total daptomycin plasma concentrations and AUC are possible (7, 27).”
BackgroundMasterton, R. G., Kuti, J. L., Turner, P. J., & Nicolau, D. P. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh511 · Cited by 62
“For comparative purposes, bactericidal pharmacodynamic breakpoints were considered to be 40%T > MIC for meropenem and imipenem, 50%T > MIC for ceftazidime, cefepime and piperacillin/tazobactam, and an AUC/ MIC ratio of 125 for ciprofloxacin.(9) – 12, 20 Statistics”
BackgroundPharmacodynamic Parameters of Pharmacokinetic/Pharmacodynamic (PK/PD) Integration Models
Zhang, L., Xie, H., Wang, Y., Wang, H., Hu, J., & Zhang, G. (2022) · Frontiers in Veterinary Science · doi:10.3389/fvets.2022.860472 · Cited by 61
When and How to Use MIC in Clinical Practice?
Magréault, S., Jauréguy, F., Carbonnelle, É., & Zahar, J. (2022) · Antibiotics · doi:10.3390/antibiotics11121748 · Cited by 62
“These targets are based on the classically described PK-PD indices with (i) timedependent antibiotics for which the index of interest is the percentage of time the free drug concentration remains above the MIC (%f T>MIC), (ii) concentration-dependent antibiotic in which it is the ratio of maximum antibiotic concentrat…”
BackgroundLepak, A. J., Reda, A., Marchillo, K., Hecker, J. V., Craig, W. A., & Andes, D. R. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03572-14 · Cited by 61
“This PK/PD target difference has been described for other drugbug combinations, but the mechanistic explanation in this case is unknown (24).”
BackgroundSelf-citation
Metadata
- Authors
- Craig, W. A.
- Affiliations
- William S. Middleton Memorial Veterans Hospital (US)
- Corresponding author
- Craig, William A.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1998-01
- Volume
- 26
- Issue
- 1
- Pages
- 1-10
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2113717321
- Cited by
- 2,908
- References
- 50
- Citations by year
- 2026: 68 · 2025: 81 · 2024: 82 · 2023: 99 · 2022: 86 · 2021: 89 · 2020: 103 · 2019: 94 · 2018: 105 · 2017: 124 · 2016: 136 · 2015: 113 · 2014: 129 · 2013: 109 · 2012: 101
- FWCI
- 54.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- pharmacokinetics/pharmacodynamics, dosing regimen, pharmacodynamic parameters, pharmacokinetic parameters, animal models of infection, human infection, susceptibility breakpoints, antimicrobial resistance, emerging pathogens, drug development costs
- MeSH terms
- Animals, Anti-Bacterial Agents, Bacteria, Humans, Lactams, Microbial Sensitivity Tests, Fluoroquinolones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.